News ArticleAlembic Pharmaceuticals Gains USFDA Final Approval for Venetoclax Tablets with 180-Day Generic Exclusivity Potential
Approval covers 10 mg, 50 mg, and 100 mg Venetoclax tablets used for CLL, SLL, and AML treatment, matching AbbVie's Venclexta
Alembic Pharmaceuticals Limited received USFDA final approval for its ANDA for Venetoclax Tablets in 10 mg, 50 mg, and 100 mg strengths, equivalent to AbbVie's Venclexta. The approval may grant Alembic 180 days of generic exclusivity for this treatment used in CLL, SLL, and AML, capturing a US market estimated at $1,584 million as of June 2026.
Alembic Pharmaceuticals Limited
New Ventures
Alembic Pharmaceuticals Limited has obtained final approval from the US Food & Drug Administration for its generic Venetoclax Tablets in three dosages, making it eligible for 180 days of market exclusivity and enabling competition against AbbVie's Venclexta in the US market.
The USFDA granted final approval to Alembic's Abbreviated New Drug Application for Venetoclax Tablets in 10 mg, 50 mg, and 100 mg strengths, recognizing therapeutic equivalence to AbbVie’s branded Venclexta Tablets.
These Venetoclax tablets are indicated for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). They are also approved, in combination with specific agents, for treating newly diagnosed acute myeloid leukemia (AML) patients aged 75 or older or those unsuitable for intensive chemotherapy.
Alembic was the first applicant to submit a substantially complete ANDA with a paragraph IV certification for Venetoclax, enabling potential 180 days of generic exclusivity upon approval.
According to IQVIA data, the market for Venetoclax tablets in the US was estimated at US $1,584 million for the twelve months ending June 2026, reflecting significant commercial opportunity.
Alembic has cumulatively received 248 ANDA approvals from the USFDA, including 228 final approvals, underscoring its regulatory expertise and product portfolio breadth.
Highlights
- Alembic's Venetoclax Tablets approved in 10 mg, 50 mg, and 100 mg doses by USFDA
- The generic is therapeutically equivalent to AbbVie’s Venclexta Tablets
- Indicated treatments include CLL, SLL, and AML for adults meeting specific criteria
- Alembic may receive 180 days of generic drug exclusivity due to paragraph IV certification
- US Venetoclax market was valued at approximately US $1,584 million for the year ending June 2026
- Alembic holds a total of 248 ANDA approvals to date
Key Data Snapshot
What happened
- Alembic Pharmaceuticals received USFDA final approval for its generic Venetoclax Tablets in 10 mg, 50 mg, and 100 mg.
- The approved ANDA is therapeutically equivalent to AbbVie's Venclexta Tablets.
- Approval qualifies Alembic for potential 180 days of generic exclusivity due to first paragraph IV certification submission.
Key details
- Venetoclax tablets treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL).
- Also indicated with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed acute myeloid leukemia (AML) patients 75 or older or with comorbidities preventing intensive chemotherapy.
- The US market for Venetoclax was estimated at US $1,584 million for the year ending June 2026.
Background and context
- Alembic Pharmaceuticals is a publicly listed Indian pharmaceutical company known for branded generics and a sizable portfolio of ANDA approvals.
- The company has received 248 USFDA ANDA approvals cumulatively, including 228 final approvals.
- This approval is part of Alembic's strategy to expand presence in the US generic pharmaceuticals market.
Highlights
- Alembic's Venetoclax Tablets approved in 10 mg, 50 mg, and 100 mg doses by USFDA
- The generic is therapeutically equivalent to AbbVie’s Venclexta Tablets
- Indicated treatments include CLL, SLL, and AML for adults meeting specific criteria
- Alembic may receive 180 days of generic drug exclusivity due to paragraph IV certification
- US Venetoclax market was valued at approximately US $1,584 million for the year ending June 2026
- Alembic holds a total of 248 ANDA approvals to date
Disclosures
- US Food & Drug Administration (USFDA) regulations governing Abbreviated New Drug Applications (ANDA) and paragraph IV certifications
More News on New Ventures
View allLatest corporate announcements and market updates in New Ventures.
HCLTech Launches AI-Powered Operations to Modernize Enterprise Mainframe Environments
HCLTech has launched its AI-Powered Operations offering aimed at helping enterprises modernize and optimize mainframe systems by incorporating AI-enabled automation, observability, and conversational AI assistants to enhance operational efficiency and proactive management.
Read Full Story
Deccan Gold Mines Reveals Preliminary Modelling of Bhalukona Deposit Indicating Over 4 Million Tonnes Nickel-Equivalent Ore
Deccan Gold Mines Limited reports that preliminary geological modelling of exploration drilling at its Bhalukona Ni-Cu-PGE deposit in Chhattisgarh suggests over 4 million tonnes of potentially economic ore containing around 0.24% nickel-equivalent grade.
Read Full Story
AGI Infra Limited Obtains Punjab RERA Approval for 'Utopia by AGI' Residential Project in New Chandigarh
AGI Infra Limited announced receipt of Real Estate Regulatory Authority (RERA) approval on October 30, 2026, for its new group housing project named 'Utopia by AGI' located in a premium residential area of New Chandigarh. This marks the company's first project in this region under the Punjab Iconic Building Policy.
Read Full Story
